Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
Public ClinicalTrials.gov record NCT02721732. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors
Study identification
- NCT ID
- NCT02721732
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 157 participants
Conditions and interventions
Conditions
- Advanced Malignant Solid Neoplasm
- Carcinoma of Unknown Primary
- Metastatic Adrenal Gland Pheochromocytoma
- Metastatic Kidney Medullary Carcinoma
- Metastatic Malignant Germ Cell Tumor
- Metastatic Malignant Solid Neoplasm
- Metastatic Paraganglioma
- Metastatic Penile Carcinoma
- Metastatic Skin Squamous Cell Carcinoma
- Small Cell Carcinoma
- Stage III Adrenal Cortex Carcinoma AJCC v7
- Stage IV Adrenal Cortex Carcinoma AJCC v7
- Stage IV Penile Cancer AJCC v7
- Stage IV Renal Cell Cancer AJCC v7
- Unresectable Adrenal Gland Pheochromocytoma
- Unresectable Paraganglioma
- Unresectable Skin Squamous Cell Carcinoma
- Unresectable Solid Neoplasm
- Vascular Neoplasm
Interventions
- Laboratory Biomarker Analysis Other
- Pembrolizumab Biological
- Questionnaire Administration Other
Other · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 14, 2016
- Primary completion
- Dec 30, 2028
- Completion
- Dec 30, 2028
- Last update posted
- Jan 28, 2026
2016 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02721732, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02721732 live on ClinicalTrials.gov.